-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2024-519786-22-01
9
metastatic non-small cell lung cancer (NSCLC)
-
2025-522855-25-00
5
Carcinoma, Transitional Cell
-
2025-523521-18-00
5
Metastatic Colorectal Cancer
-
2025-522093-36-00
10
2026-05-20
Cancer cachexia
-
2025-521639-34-00
3
2026-04-20
• Non-small cell lung cancer (Stage III, unresectable)
• Small cell lu
-
2024-512248-47-00
9
2026-04-15
Non-small Cell Lung Cancer (NSCLC)
-
2025-520902-37-00
4
2026-04-01
Non-small cell lung cancer stage IV
-
2025-521939-36-00
4
2026-03-03
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-520582-51-00
5
2025-10-17
Hormone receptor positive breast cancer
-
2024-518839-11-00
4
2025-08-25
Stage IV Squamous Non-Small Cell Lung Cancer
-
2024-514048-98-00
5
2025-01-30
Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cance
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2024-520026-11-00
7
2026-03-19
Metastatic Prostate Cancer
-
2024-518210-81-00
5
2026-03-18
Advanced Hepatocellular Carcinoma
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2025-521737-91-00
4
2025-11-25
Neoplasm malignant with KRAS G12C mutation